Answers are grounded in this paper and cite their sources.
Cyclophosphamide is the mainstay treatment for patients with lupus nephritis (LN); it can be prescribed at lower doses than the recommended regimen to avoid side effects. We aimed to investigate the impact of cyclophosphamide dosing strategies on treatment outcomes of patients with LN initially treated with a lower-than-recommended dose.
No takes yet. Share an insight, caveat, or question.
Chienwichai et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: